XIANYANG, China, Feb. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) (“Biostar” or “the Company”), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules (“Xin Aoxing Capsules”), today announced that it will present at the Rodman & Renshaw Annual China Investment Conference, to be held March 6-8, 2011, at the Le Royal Meridien Shanghai in Shanghai, China.
Mr. Bill Chen, Chief Financial Officer, will present on behalf of the Company on Tuesday, March 8, 2011, at 11:05 am. The Company management will also participate in one-on-one meetings with analysts and investors. The presentation will be webcast live and a replay will be archived on the company’s investor relations website at www.biostarpharmaceuticals.com.
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar currently manufactures two broad-based OTC products, two prescription-based pharmaceuticals, one medical device and five health supplements.
For further information, contact: Bill Chen (Deyin), CFO Ted Haberfield | |
SOURCE Biostar Pharmaceuticals, Inc.
